3月17日,比利时生物技术公司EsoBiotec SA公告,宣布已达成最终协议,将被阿斯利康以高达10亿美元(约72.4亿元)的总对价收购。根据财务条款,阿斯利康将在无现金和无债务的基础上收购EsoBiotec的所有未偿股权,并以10亿美元的总对价收购其所有已发行股权。这笔交易首付款为4.25亿美元,并根据监管和里程碑计算剩余5.75亿美元的或有对价。该交易将在监管许可后,于2025年第二季度完成...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.